Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-07-24
2007-07-24
Foley, Shanon (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S387700, C530S388100
Reexamination Certificate
active
10642118
ABSTRACT:
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
REFERENCES:
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 6300308 (2001-10-01), Schroit
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6783760 (2004-08-01), Thorpe et al.
patent: 6806354 (2004-10-01), Schroit
patent: 6818213 (2004-11-01), Thorpe et al.
patent: 7067109 (2006-06-01), Thorpe et al.
patent: 2002/0025319 (2002-02-01), Brams
patent: 2003/0004097 (2003-01-01), Schroit
patent: 2003/0228625 (2003-12-01), Toh et al.
patent: 2004/0131621 (2004-07-01), Thorpe et al.
patent: 2004/0131622 (2004-07-01), Thorpe et al.
patent: 2004/0161429 (2004-08-01), Thorpe et al.
patent: 2004/0170620 (2004-09-01), Thorpe et al.
patent: 2004/0175378 (2004-09-01), Thorpe et al.
patent: 2004/0219155 (2004-11-01), Thorpe et al.
patent: 2004/0265367 (2004-12-01), Thorpe et al.
patent: 2005/0002941 (2005-01-01), Thorpe et al.
patent: 2005/0031620 (2005-02-01), Thorpe et al.
patent: 2005/0129696 (2005-06-01), Thorpe et al.
patent: 2005/0136059 (2005-06-01), Thorpe et al.
patent: WO 00/02584 (2000-01-01), None
patent: WO 00/02587 (2000-01-01), None
patent: WO 01/03735 (2001-01-01), None
patent: WO 01/68709 (2001-09-01), None
Janeway et al (Immunobiology, 2001, 5th Ed., Garland Publishing, New York) pp. 1-2 and 1-5.
Rudikoff et al, PNAS, USA, 1982, 79: 1979-83.
Gura (Science, 1997, 278:1041-1042).
Mellman (The Scientist, 2006, 20:47; internet pages 1-10).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Ran et al (Clinical Cancer Research, 2005, 11:1551-1562).
Luster et al (J of Biological Chemistry, 2006).
Balasubramanian and Schroit, “Aminophospholipid Asymmetry: A Matter of Life and Death”,Annu. Rev. Physiol., 65:701-734, 2003.
Beck et al., “Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemcitabine Strongly Inhibits the Growth and Metastasis or Orthotopic Pancreatic Tumors in Mice”,Int. J. Cancer, 118:2639-2643, 2006.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amnio Acid Substitutions”,Science, 147:1306-1310, 1990.
Goren et al., “Targeting of Stealth Liposomes in erbB-2 (HER/2) Receptor: In Vitro and In Vivo Sudies”,Brit. J. Cancer, 74:1749-1756, 1996.
Güssow and Seemann, “Humanization of Monoclonal Antibodies”,Methods in Enzymology, 203:99-121, 1991.
Herbert et al., Eds., Dictionary of Immunology, 4th ed. London:Academic Press, 1995.
Huang et al., “A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice”,Cancer Res., 65(10):4408-4416, 2005.
Ishida et al., A Combinatorial Approach to Producing Sterically Stabilized (Stealth) Immunoliposomal Drugs,FEBS Letters, 460:129-133, 1999.
Lewis et al., “Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies”,Cancer Immunol. Immunother., 37:255-263, 1993.
Luster et al., “Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells,”JBC Papers in Press, www.jbc.org/cgi/doi/10.1074/jbc., M605252200:1-20, 2006.
Maneta-Peyret et al., “Demonstration of High Specificity Antibodies Against Phosphatidylserine”,J. Immunol. Methods, 108:123-127, 1988.
Maruyama et al., “Lipid Composition is Important for Highly Efficient Target Binding and Retention of Immunoliposomes”,Proc. Natl. Acad. Sci. USA, 87:5744-5748, 1990.
Ran and Thorpe, “Phosphatidylserine is a Marker of Tumor Vasculature and a Potential Target for Cancer Imaging and Therapy”,Int. J. Radiation Oncology Biol. Phys., 54(5):1479-1484, 2002.
Ran et al., “Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice”,Clin. Cancer Res., 11:1551-1562, 2005.
Ran et al., “Increased Exposure of Anionic Phospholipids on the Surface of the Tumor Blood Vessels”,Cancer Res.; 62:6132-6140, 2002.
Rote et al., “Immunologic Detection of Phosphatidylserine Externalization During Thrombin-Induced Platelet Activation”,Clinical Immunology and Immunopathology, 66:193-200, 1993.
Schneider-Gadicke and Riethmüller, “Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours”,Eur. J. Cancer, 31A(7/8):1326-1330, 1995.
Stancovski et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth”,Proc. Natl. Acad. Sci. USA, 88:8691-8695, 1991.
Strobel and Cannsitra, “β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro”,Gynecologic Oncology, 73:362-367, 1999.
Thorpe et al., “Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors”,Proceedings of the American Association for Cancer Research, 36:488, Abstract #2910, Mar. 1995.
Umeda et al., “Effective Production of Monoclonal Antibodies Against Phosphatidylserine: Stereo-Specific Recognition of Phosphatidylserine by Monoclonal Antibody”,J. Immunol., 143:2273-2279, 1989.
Contractual European Search Report for counterpart PCT Application, PCT/US03/21925, mailed Mar. 31, 2004.
European Search Report for Counterpart European Application No. 03764600.7, dated Dec. 27, 2004.
International Search Report for counterpart PCT Application, PCT/US03/21925, mailed Feb. 24, 2005.
Ran Sophia
Thorpe Philip E.
Board of Regents , The University of Texas System
Foley Shanon
Fussey Shelley P.M.
Goddard Laura B
LandOfFree
Selected antibody CDRs for binding to aminophospholipids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selected antibody CDRs for binding to aminophospholipids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selected antibody CDRs for binding to aminophospholipids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808033